You are here

Innovation Grants

These grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. A Letter of Intent is required. The Innovation Award amount totals $250,000 over two years. The Award may not be renewed, however, one no cost extensions are allowable.

Modeling and Therapeutic Targeting of p21-Activated Kinase Members in High-Risk Rhabdomyosarcoma

Background

Principal Investigator Name: 

Jason Yustein, MD/PhD

Project Title: 

Modeling and Therapeutic Targeting of p21-Activated Kinase Members in High-Risk Rhabdomyosarcoma

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Energy Balance Strategies for Decreasing Chemotherapy-Induced Cardiotoxicity

Background
Advances in chemotherapy strategies have improved survival rates for childhood cancer to 80%. However, there are >400,000 survivors where cardiac disease related to cancer therapy is the leading cause of mortality. There is a correlation between total dose of doxorubicin (Dox) and overall survival in children with sarcomas but also a direct link between Dox dose and subsequent cardiac morbidity. We demonstrated that exercise during Dox decreased acute cardiac damage without interfering with Dox efficacy. 

Principal Investigator Name: 

Eugenie Kleinerman, MD

Project Title: 

Energy Balance Strategies for Decreasing Chemotherapy-Induced Cardiotoxicity

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Nuclear Receptor Tyrosine Kinases Mediating Chromatin Remodeling & Checkpoint Adaption

Background
Alveolar rhabdomyosarcoma is a cancer of the soft tissues. This disease often responds to chemotherapy, but in many patients the available treatments fail – a deadly outcome. We identified how a cancer-causing fusion gene called Pax3:Foxo1 may lead to treatment failure: by turning on growth factor genes late in the process of tumor cell duplication. We believe this pro-growth, pro-survival process allows tumor cells to endure chemotherapy and radiation and allow tumor recurrences. 

Principal Investigator Name: 

Charles Keller, MD

Project Title: 

Nuclear Receptor Tyrosine Kinases Mediating Chromatin Remodeling & Checkpoint Adaption

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas

Background

Principal Investigator Name: 

Tamra Werbowetski-Ogilvie, PhD

Project Title: 

Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Alternative Splicing in the Pathogenesis of Acute Lymphoblastic Leukemia

Background

Principal Investigator Name: 

Andrei Thomas-Tikhonenko, PhD

Project Title: 

Alternative Splicing in the Pathogenesis of Acute Lymphoblastic Leukemia

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

De-escalation of Radiotherapy for Medulloblastoma by a Novel DNA Damage Checkpoint Inhibitor

Background
Medulloblastoma is the most common malignant pediatric brain tumor. Radiotherapy is effective for a large number of medulloblastoma patients, but it often has devastating life-long side effects that severely limit the quality of life of these patients. Thus, safer therapies are urgently needed. 

Principal Investigator Name: 

Marc Symons, PhD

Project Title: 

De-escalation of Radiotherapy for Medulloblastoma by a Novel DNA Damage Checkpoint Inhibitor

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pages